Despite the Downward Trend in Earnings at Xilong Scientific (SZSE:002584) the Stock Spikes 48%, Bringing Five-year Gains to 93%
Despite the Downward Trend in Earnings at Xilong Scientific (SZSE:002584) the Stock Spikes 48%, Bringing Five-year Gains to 93%
Stock pickers are generally looking for stocks that will outperform the broader market. And while active stock picking involves risks (and requires diversification) it can also provide excess returns. For example, the Xilong Scientific Co., Ltd. (SZSE:002584) share price is up 93% in the last 5 years, clearly besting the market return of around 37% (ignoring dividends). On the other hand, the more recent gains haven't been so impressive, with shareholders gaining just 74%.
选股者通常在寻找表现优于大盘的股票。尽管主动选股涉及风险(需要多元化),但它也可以提供超额回报。例如,西隆科学有限公司(SZSE:002584)的股价在过去5年中上涨了93%,显然超过了约37%的市场回报率(不包括股息)。另一方面,最近的涨幅并不那么令人印象深刻,股东仅上涨了74%。
Since it's been a strong week for Xilong Scientific shareholders, let's have a look at trend of the longer term fundamentals.
由于对于Xilong Scientific的股东来说,这是表现强劲的一周,让我们来看看长期基本面的走势。
View our latest analysis for Xilong Scientific
查看我们对希隆科学的最新分析
Given that Xilong Scientific only made minimal earnings in the last twelve months, we'll focus on revenue to gauge its business development. As a general rule, we think this kind of company is more comparable to loss-making stocks, since the actual profit is so low. For shareholders to have confidence a company will grow profits significantly, it must grow revenue.
鉴于Xilong Scientific在过去十二个月中仅获得最低收益,我们将重点关注收入来衡量其业务发展。一般而言,我们认为这种公司更能与亏损股票相提并论,因为实际利润太低了。为了让股东有信心公司大幅增加利润,它必须增加收入。
In the last 5 years Xilong Scientific saw its revenue grow at 15% per year. That's well above most pre-profit companies. While the compound gain of 14% per year is good, it's not unreasonable given the strong revenue growth. If you think there could be more growth to come, now might be the time to take a close look at Xilong Scientific. Opportunity lies where the market hasn't fully priced growth in the underlying business.
在过去的5年中,希隆科学的收入以每年15%的速度增长。这远高于大多数预盈利公司。尽管每年14%的复合收益不错,但鉴于强劲的收入增长,这并非没有道理。如果你认为未来可能会有更多的增长,那么现在可能是仔细研究西隆科学的时候了。机会在于市场尚未对标的业务增长进行全面定价的地方。
You can see how earnings and revenue have changed over time in the image below (click on the chart to see the exact values).
您可以在下图中看到收入和收入随时间推移而发生的变化(点击图表查看确切值)。
![earnings-and-revenue-growth](https://usnewsfile.moomoo.com/public/MM-PersistNewsContentImage/7781/20231121/0-3fcaa4f48a9128055f78828ab97c5097-0-dab1d179a2465f27f95589e2b54cbfa0.png/big)
We're pleased to report that the CEO is remunerated more modestly than most CEOs at similarly capitalized companies. It's always worth keeping an eye on CEO pay, but a more important question is whether the company will grow earnings throughout the years. It might be well worthwhile taking a look at our free report on Xilong Scientific's earnings, revenue and cash flow.
我们很高兴地向大家报告,首席执行官的薪酬比资本状况相似的公司的大多数首席执行官更适中。始终值得关注首席执行官的薪酬,但更重要的问题是公司多年来是否会增加收益。我们关于Xilong Scientific的收益、收入和现金流的免费报告可能值得一看。
A Different Perspective
不同的视角
It's good to see that Xilong Scientific has rewarded shareholders with a total shareholder return of 74% in the last twelve months. Since the one-year TSR is better than the five-year TSR (the latter coming in at 14% per year), it would seem that the stock's performance has improved in recent times. Given the share price momentum remains strong, it might be worth taking a closer look at the stock, lest you miss an opportunity. I find it very interesting to look at share price over the long term as a proxy for business performance. But to truly gain insight, we need to consider other information, too. Consider for instance, the ever-present spectre of investment risk. We've identified 3 warning signs with Xilong Scientific (at least 1 which is significant) , and understanding them should be part of your investment process.
很高兴看到希隆科学在过去十二个月中向股东提供了74%的股东总回报率。由于一年期股东总回报率好于五年期股东总回报率(后者为每年14%),该股的表现似乎在最近有所改善。鉴于股价势头仍然强劲,可能值得仔细研究该股,以免错过机会。我发现从长远来看,将股价视为业务表现的代表非常有趣。但是,要真正获得见解,我们还需要考虑其他信息。例如,以永远存在的投资风险幽灵为例。我们已经确定了希隆科学的三个警告信号(至少有一个很重要),了解它们应该成为您投资过程的一部分。
Of course, you might find a fantastic investment by looking elsewhere. So take a peek at this free list of companies we expect will grow earnings.
当然,通过寻找其他地方,你可能会找到一笔不错的投资。因此,请看一下我们预计收益将增加的这份免费公司名单。
Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on Chinese exchanges.
请注意,本文引用的市场回报反映了目前在中国交易所交易的股票的市场加权平均回报。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
对这篇文章有反馈吗?对内容感到担忧?直接联系我们。 或者,给编辑团队 (at) simplywallst.com 发送电子邮件。
Simply Wall St的这篇文章本质上是笼统的。我们仅使用公正的方法根据历史数据和分析师的预测提供评论,我们的文章无意作为财务建议。它不构成买入或卖出任何股票的建议,也没有考虑到您的目标或财务状况。我们的目标是为您提供由基本数据驱动的长期重点分析。请注意,我们的分析可能不考虑最新的价格敏感型公司公告或定性材料。简而言之,华尔街没有持有任何上述股票的头寸。